Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032

Seasonal influenza (SI) is a contagious respiratory viral illness. There are four types of SI viruses: A, B, C, and D; however, only types A and B cause human disease of public health concern (WHO, 2023). Influenza transmission occurs when people with the flu cough, sneeze, or talk, thereby disseminating droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2022).

Symptoms of influenza are headache, fever, cough, sore throat, and aching muscles and joints. The influenza virus tends to cause more severe disease in infants, elderly people, young children, and those with a weakened immune system (WHO, 2023). The World Health Organization (WHO) estimates that approximately 5-10% of adults and 20-30% of children are affected by an influenza-like illness (ILI) annually (WHO, 2023).

Scope

Seasonal Influenza (SI) vaccines Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza- like illness (ILI), and lab-confirmed SI segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years).Seasonal Influenza (SI) vaccines Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza- like illness (ILI), and lab-confirmed SI segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0-4 years, 5-17 years, 18-64 years, and ≥65 years).

Reasons to Buy

Seasonal influneza vaccines epidemiology series will allow you to -
Develop business strategies by understanding the trends shaping and driving the global SI vaccines markets.
Quantify patient populations in the global SI markets to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SI therapeutics in each of the markets covered.

Product Code: GDHCER312-23

1 Seasonal Influenza Vaccines: Executive Summary

1.1Catalyst
1.2 Related Reports
1.3 Upcoming Reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of ILI
- 2.4.4 Forecast assumptions and methods: diagnosed incident cases of lab-confirmed SI
- 2.4.5 SI vaccinated population
2.5 Epidemiological forecast for ILI, lab-confirmed SI, and SI vaccinated population (2022–32)
- 2.5.1 Diagnosed incident cases of ILI
- 2.5.2 Age-specific diagnosed incident cases of ILI
- 2.5.3 Sex-specific diagnosed incident cases of ILI
- 2.5.4 Diagnosed incident cases of lab-confirmed SI
- 2.5.5 Age-specific diagnosed incident cases of lab-confirmed SI
- 2.5.6 Sex-specific diagnosed incident cases of lab-confirmed SI
- 2.5.7 SI vaccinated population
- 2.5.8 Age-specific SI vaccinated population
2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 COVID-19 impact
- 2.6.3 Limitations of the analysis
- 2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 About the Authors
- 3.2.1 Epidemiologist
- 3.2.2 Reviewers
- 3.2.3 Vice President of Disease Intelligence and Epidemiology

Product Code: GDHCER312-23

List of Tables

Table 1: Summary of updated data types
Table 2: Risk factors and comorbidities for SI

List of Figures

Figure 1: 7MM, diagnosed incident cases of lab-confirmed influenza, both sexes and all ages, N, 2022 and 2032
Figure 2: 7MM, SI vaccinated cases, both sexes and all ages, N, 2022 and 2032
Figure 3: 7MM, diagnosed incidence of lab-confirmed SI, both sexes, cases per 100,000 population, all ages, 2012-32
Figure 4: 7MM, SI vaccination rate, both sexes, %, all ages, 2012-32
Figure 5: 7MM, sources used to forecast diagnosed incident cases of ILI
Figure 6: 7MM, sources used to forecast diagnosed incident cases of lab-confirmed SI
Figure 7: 7MM, sources used in SI vaccinated population
Figure 8: 7MM, diagnosed incident cases of ILI, N, both sexes, all ages, 2022Figure 9: 7MM, diagnosed incident cases of ILI by age, N, both sexes, 2022
Figure 10: 7MM, diagnosed incident cases of ILI by sex, N, all ages, 2022Figure 11: 7MM, diagnosed incident cases of lab-confirmed SI, N, both sexes, all ages, 2022
Figure 12: 7MM, diagnosed incident cases of lab-confirmed SI by age, N, both sexes, 2022
Figure 13: 7MM, diagnosed incident cases of lab-confirmed SI by sex, N, all ages, 2022
Figure 14: 7MM, SI vaccinated population, N, both sexes, all ages, 2022
Figure 15: 7MM, SI vaccinated population by age, N, both sexes, 2022

Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032

Description

Table of Contents

List of Tables

Abstract

Scope

Reasons to Buy

Table of Contents

1 Seasonal Influenza Vaccines: Executive Summary

2 Epidemiology

3 Appendix

List of Tables

List of Tables

List of Figures

List of Figures